AbbVie Reports Strong Q2 2025 Results Driven by Robust Sales of Skyrizi and Rinvoq, Raises Full-Year Guidance

Intelligent Finance APP learned that AbbVie (ABBV.US) announced better-than-expectedThe Second QuarterPerformance, and raised the full-year profit forecast, as the company's newer immunology drugs offset a sharp decline in sales of its blockbuster arthritis treatment, Humira.

The financial report shows that in the second quarterRevenue of $15.42 billion, a year-on-year increase of 6.6%, exceeding market expectations by $390 million;Earnings per share of $2.97 on a non-GAAP basis, exceeding market expectations by $0.06.

After adjustment, the company's gross margin in the second quarter was 84.4%, and the operating profit margin was 44.3%.

Global Immunology Portfolio Net Revenue in Q2: $7.631 Billion, Up 9.5% on a Reported Basis and 9.2% on an Operational Basis; While Humira's Net Revenue Plummeted 58% Year-over-Year to $1.2 Billion, Skyrizi and Rinvoq Generated $4.4 Billion and $2 Billion Respectively, with Year-over-Year Growth of Approximately 62% and 42%.

Meanwhile, AbbVie's neuroscience portfolio achieved net revenue of $2.7 billion, representing a year-over-year increase of approximately 24%. Despite a 10% year-over-year decline in sales of Imbruvica, the leukemia treatment drug co-developed with Johnson & Johnson, the company’s oncology portfolio saw an increase in net revenue of $1.7 billion, reflecting a year-over-year growth of about 3%.

AbbVie alsoRaised 2025 Adjusted Diluted Earnings Per Share Guidance: Increased from the original $11.67-$11.87 to $11.88-$12.08 (Market consensus expectation is $11.98).